rebel Financial rebel Financial
← All Posts
NTLA

Intellia Therapeutics, Inc.

June 10, 2026 • Author: Phil Ratcliff • NTLA
Item Proposal Vote
1 Election of three class I directors to our board of directors, each to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal.
1a Muna Bhanji, R.Ph. ✓ For
1b Brian Goff ✓ For
1c Jesse Goodman, M.D., M.P.H. ✓ For
2 Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. ✓ For
3 Approval, on a non-binding advisory basis, of the compensation of our named executive officers. ✓ For
4 The transaction of such other business as may properly come before the meeting. ✗ Against
Attachments
📄
NTLA_PROXY_STATEMENT.pdf 0.7 MB
📄
NTLA_ANNUAL_REPORT_2025.pdf 0.8 MB
This article was written for information purposes only and its content should not be construed by any consumer and/or prospective client as rebel Financial's solicitation to affect, or attempt to affect transactions in securities, or the rendering of personalized investment advice for compensation. No client or prospective client should assume that any such discussion serves as the receipt of, or a substitute for, personalized advice from rebel Financial, or from any other investment professional. See our disclosures page for more information.